Literature DB >> 27462073

Cell Damage in Light Chain Amyloidosis: FIBRIL INTERNALIZATION, TOXICITY AND CELL-MEDIATED SEEDING.

Marta Marin-Argany1, Yi Lin2, Pinaki Misra1, Angela Williams3, Jonathan S Wall3, Kyle G Howell4, Laura R Elsbernd5, Megan McClure6, Marina Ramirez-Alvarado7.   

Abstract

Light chain (AL) amyloidosis is an incurable human disease characterized by the misfolding, aggregation, and systemic deposition of amyloid composed of immunoglobulin light chains (LC). This work describes our studies on potential mechanisms of AL cytotoxicity. We have studied the internalization of AL soluble proteins and amyloid fibrils into human AC16 cardiomyocytes by using real time live cell image analysis. Our results show how external amyloid aggregates rapidly surround the cells and act as a recruitment point for soluble protein, triggering the amyloid fibril elongation. Soluble protein and external aggregates are internalized into AC16 cells via macropinocytosis. AL amyloid fibrils are shown to be highly cytotoxic at low concentrations. Additionally, caspase assays revealed soluble protein induces apoptosis, demonstrating different cytotoxic mechanisms between soluble protein and amyloid aggregates. This study emphasizes the complex immunoglobulin light chain-cell interactions that result in fibril internalization, protein recruitment, and cytotoxicity that may occur in AL amyloidosis.
© 2016 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  amyloid; apoptosis; cardiomyocytes; cell internalization; endocytosis; fibril fragmentation; in vivo imaging; light chain amyloidosis; protein aggregation; toxicity

Mesh:

Substances:

Year:  2016        PMID: 27462073      PMCID: PMC5025671          DOI: 10.1074/jbc.M116.736736

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  69 in total

1.  Structural basis of light chain amyloidogenicity: comparison of the thermodynamic properties, fibrillogenic potential and tertiary structural features of four Vlambda6 proteins.

Authors:  Jonathan S Wall; Vibha Gupta; Matthew Wilkerson; Maria Schell; Remy Loris; Paul Adams; Alan Solomon; Fred Stevens; Chris Dealwis
Journal:  J Mol Recognit       Date:  2004 Jul-Aug       Impact factor: 2.137

2.  Amyloid formation in human islets is enhanced by heparin and inhibited by heparinase.

Authors:  K J Potter; I Werner; H C Denroche; J Montane; A Plesner; Y Chen; D Lei; G Soukhatcheva; G L Warnock; J Oberholzer; P E Fraser; C B Verchere
Journal:  Am J Transplant       Date:  2015-04-01       Impact factor: 8.086

3.  Novel cell lines derived from adult human ventricular cardiomyocytes.

Authors:  Mercy M Davidson; Claudia Nesti; Lluis Palenzuela; Winsome F Walker; Evelyn Hernandez; Lev Protas; Michio Hirano; Nithila D Isaac
Journal:  J Mol Cell Cardiol       Date:  2005-07       Impact factor: 5.000

4.  Use of dynasore, the small molecule inhibitor of dynamin, in the regulation of endocytosis.

Authors:  Tom Kirchhausen; Eric Macia; Henry E Pelish
Journal:  Methods Enzymol       Date:  2008       Impact factor: 1.600

5.  Fragments of the constant region of immunoglobulin light chains are constituents of AL-amyloid proteins.

Authors:  K E Olsen; K Sletten; P Westermark
Journal:  Biochem Biophys Res Commun       Date:  1998-10-20       Impact factor: 3.575

6.  Selective transfer of exosomes from oligodendrocytes to microglia by macropinocytosis.

Authors:  Dirk Fitzner; Mareike Schnaars; Denise van Rossum; Gurumoorthy Krishnamoorthy; Payam Dibaj; Mostafa Bakhti; Tommy Regen; Uwe-Karsten Hanisch; Mikael Simons
Journal:  J Cell Sci       Date:  2011-02-01       Impact factor: 5.285

7.  Physical and chemical properties of amyloid fibers. II. Isolation of a unique protein constituting the major component from human splenic amyloid fibril concentrates.

Authors:  G G Glenner; P Cuatrecasas; C Isersky; H A Bladen; E D Eanes
Journal:  J Histochem Cytochem       Date:  1969-12       Impact factor: 2.479

8.  Molecular structure of β-amyloid fibrils in Alzheimer's disease brain tissue.

Authors:  Jun-Xia Lu; Wei Qiang; Wai-Ming Yau; Charles D Schwieters; Stephen C Meredith; Robert Tycko
Journal:  Cell       Date:  2013-09-12       Impact factor: 41.582

9.  Laser microdissection and mass spectrometry-based proteomics aids the diagnosis and typing of renal amyloidosis.

Authors:  Sanjeev Sethi; Julie A Vrana; Jason D Theis; Nelson Leung; Anjali Sethi; Samih H Nasr; Fernando C Fervenza; Lynn D Cornell; Mary E Fidler; Ahmet Dogan
Journal:  Kidney Int       Date:  2012-04-11       Impact factor: 10.612

10.  Light Chain Amyloid Fibrils Cause Metabolic Dysfunction in Human Cardiomyocytes.

Authors:  Helen P McWilliams-Koeppen; James S Foster; Nicole Hackenbrack; Marina Ramirez-Alvarado; Dallas Donohoe; Angela Williams; Sallie Macy; Craig Wooliver; Dale Wortham; Jennifer Morrell-Falvey; Carmen M Foster; Stephen J Kennel; Jonathan S Wall
Journal:  PLoS One       Date:  2015-09-22       Impact factor: 3.240

View more
  28 in total

1.  Amyloid seeding of transthyretin by ex vivo cardiac fibrils and its inhibition.

Authors:  Lorena Saelices; Kevin Chung; Ji H Lee; Whitaker Cohn; Julian P Whitelegge; Merrill D Benson; David S Eisenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2018-06-28       Impact factor: 11.205

2.  Differences in Protein Concentration Dependence for Nucleation and Elongation in Light Chain Amyloid Formation.

Authors:  Luis M Blancas-Mejía; Pinaki Misra; Marina Ramirez-Alvarado
Journal:  Biochemistry       Date:  2017-01-24       Impact factor: 3.162

Review 3.  AL amyloidosis: from molecular mechanisms to targeted therapies.

Authors:  Giampaolo Merlini
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

4.  Mechanistic Insights into the Early Events in the Aggregation of Immunoglobulin Light Chains.

Authors:  Pinaki Misra; Luis M Blancas-Mejia; Marina Ramirez-Alvarado
Journal:  Biochemistry       Date:  2019-07-09       Impact factor: 3.162

5.  Phase 2 trial of daily, oral epigallocatechin gallate in patients with light-chain amyloidosis.

Authors:  Sohsuke Meshitsuka; Sumito Shingaki; Masatoshi Hotta; Miku Goto; Makoto Kobayashi; Yuuichi Ukawa; Yuko M Sagesaka; Yasuyo Wada; Masanori Nojima; Kenshi Suzuki
Journal:  Int J Hematol       Date:  2016-11-04       Impact factor: 2.490

6.  Fatal amyloid formation in a patient's antibody light chain is caused by a single point mutation.

Authors:  Pamina Kazman; Marie-Theres Vielberg; María Daniela Pulido Cendales; Lioba Hunziger; Benedikt Weber; Ute Hegenbart; Martin Zacharias; Rolf Köhler; Stefan Schönland; Michael Groll; Johannes Buchner
Journal:  Elife       Date:  2020-03-10       Impact factor: 8.140

Review 7.  Immunoglobulin light chain amyloid aggregation.

Authors:  Luis M Blancas-Mejia; Pinaki Misra; Christopher J Dick; Shawna A Cooper; Keely R Redhage; Michael R Bergman; Torri L Jordan; Khansaa Maar; Marina Ramirez-Alvarado
Journal:  Chem Commun (Camb)       Date:  2018-09-20       Impact factor: 6.222

8.  Assays for Light Chain Amyloidosis Formation and Cytotoxicity.

Authors:  Luis M Blancas-Mejia; Pinaki Misra; Christopher J Dick; Marta Marin-Argany; Keely R Redhage; Shawna A Cooper; Marina Ramirez-Alvarado
Journal:  Methods Mol Biol       Date:  2019

9.  Light chain amyloidosis induced inflammatory changes in cardiomyocytes and adipose-derived mesenchymal stromal cells.

Authors:  Torri L Jordan; Khansaa Maar; Keely R Redhage; Pinaki Misra; Luis M Blancas-Mejia; Christopher J Dick; Jonathan S Wall; Angela Williams; Allan B Dietz; Andre J van Wijnen; Yi Lin; Marina Ramirez-Alvarado
Journal:  Leukemia       Date:  2019-12-03       Impact factor: 11.528

10.  Bifunctional amyloid-reactive peptide promotes binding of antibody 11-1F4 to diverse amyloid types and enhances therapeutic efficacy.

Authors:  Jonathan S Wall; Angela D Williams; James S Foster; Tina Richey; Alan Stuckey; Sallie Macy; Craig Wooliver; Shawn R Campagna; Eric D Tague; Abigail T Farmer; Ronald H Lands; Emily B Martin; R Eric Heidel; Stephen J Kennel
Journal:  Proc Natl Acad Sci U S A       Date:  2018-10-30       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.